PURE Bioscience 10-K: Auditors Flag Going Concern as Cash Falls to $569,000
PURE has more than doubled off its 52-week low of $0.039 on light trading volume (0.2× avg).
Summary
PURE Bioscience's fiscal 2026 10-K carries a going-concern opinion: sales rose 5% to $2.32 million but the net loss widened to $2.48 million, leaving $569,000 of cash against $1.0 million of past-due related-party notes.
Key Events · Earnings and Guidance · PURE
-
Auditors Raise Going-Concern Doubt
The audit report cites recurring losses, negative operating cash flow and a $6,399,000 stockholders' deficiency at July 31, 2026 as substantial doubt about continuing as a going concern.
-
Cash Thin, Related-Party Notes Past Due
Cash stood at $569,000 against $7,592,000 of total liabilities, including $3,381,000 of current convertible notes to related parties, of which $1,015,000 is past due.
-
Sales Up 5%, Loss Widens
Net product sales rose to $2,315,000 from $2,198,000, but the net loss widened to $2,483,000 from $2,399,000 and operating cash use was $1,738,000.
-
Share Count and Overhang Grow
Shares outstanding reached 140,201,055 as of October 29, 2026 versus 130,017,569 at July 31, 2026, with 73,630,663 anti-dilutive shares (including 59,523,163 issuable on debt conversion) excluded from diluted EPS.
Analysis · PURE · Industrial Applications And Services
The annual report lays out the survival math in plain terms. PURE closed fiscal 2026 with $569,000 of cash after burning $1,738,000 in operations, against $7,592,000 of liabilities — including $1,015,000 of related-party convertible notes already past due — and a $6,399,000 stockholders' deficiency. With the auditors adding a going-concern paragraph, the company must keep raising money from director Tom Y. Lee and other accredited investors, and every raise lands on a share base that has already grown to 140,201,055 shares from 111,886,473 a year earlier. Sales growth of 5% to $2,315,000 does not come close to covering a $2,483,000 net loss, and the $5.8 million of convertible notes can convert at VWAP-based prices as low as $0.07, so the equity overhang is the central risk.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PURE was trading at $0.08 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $10.2M. The 52-week trading range was $0.04 to $0.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.